Persistent EBNA-1 peptide IgG antibody levels may help distinguish multiple sclerosis from other neuroinflammatory diseases like MOGAD and NMOSD.

A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

Though relapsing-remitting multiple sclerosis, or RRMS, can be managed with many of the approved treatments for MS symptoms, there is still no scientifically proven, FDA-cleared way to predict when or ...

A test that measures kappa immunoglobulin free light chains in cerebrospinal fluid (KCSF) is a valid option for diagnosing multiple sclerosis (MS), new research suggests. Results showed that compared ...

An estimated 2.8 million people worldwide have multiple sclerosis (MS). This autoimmune condition is the result of the immune system damaging parts of the nerves in the brain and spinal cord, which ...

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the ...

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics "According to the National Multiple Sclerosis Society, ...

A previously "hidden" subtype of Multiple Sclerosis (MS)—a condition that affects the brain and spinal cord—has been uncovered. The distinct subtype exhibits "significant cognitive deficits with ...

Multiple sclerosis (MS) is a debilitating neurological disorder caused by malfunctioning immune responses that target the ...

Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain ...